Skip to main content
Top
Published in: European Journal of Clinical Microbiology & Infectious Diseases 5/2018

01-05-2018 | Editorial

Antibiotic treatment and stewardship in the era of microbiota-oriented diagnostics

Authors: Debby Bogaert, Alex van Belkum

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 5/2018

Login to get access

Excerpt

Antibiotics are key to the battle against infectious diseases by their capacity to completely block or attenuate microbial growth. Their use is widely accepted and has saved many lives. Still, antibiotic treatment has obvious downsides. For instance, (severe) allergic reactions have been documented and most if not all antibiotics have toxic side effects [1]. Moreover, antibiotics do not specifically target single bacterial species, instead they may extinguish entire (mixed) populations of bacteria. Many of such populations are considered physiologically important. These so-called microbiota, inhabiting all niches in and on our body, are known to have clear and mostly beneficial health effects. Our microbiota, defined as the total ecological community of commensal, symbiotic, and pathogenic microorganisms that inhabit us, are most commonly composed of a mixture of Firmicutes, Bacteroidetes, Actinobacteria, and Proteobacteria. Recent nucleic acid sequencing-based efforts have shown great progress in cataloguing this diversity of microbial species: this made us realize that until then, we had only been scratching the surface in identifying human-associated microbes, and had only been assured that many more species are still left to be discovered [2]. …
Literature
1.
go back to reference Björnsson ES (2017) Drug-induced liver injury due to antibiotics. Scand J Gastroenterol 52(6–7):617–623CrossRefPubMed Björnsson ES (2017) Drug-induced liver injury due to antibiotics. Scand J Gastroenterol 52(6–7):617–623CrossRefPubMed
2.
go back to reference Hugon P, Dufour JC, Colson P, Fournier PE, Sallah K, Raoult D (2015) A comprehensive repertoire of prokaryotic species identified in human beings. Lancet Infect Dis 15(10):1211–1219CrossRefPubMed Hugon P, Dufour JC, Colson P, Fournier PE, Sallah K, Raoult D (2015) A comprehensive repertoire of prokaryotic species identified in human beings. Lancet Infect Dis 15(10):1211–1219CrossRefPubMed
3.
go back to reference Ruppé E, Burdet C, Grall N, de Lastours V, Lescure FX, Andremont A, Armand-Lefèvre L (2018) Impact of antibiotics on the intestinal microbiota needs to be re-defined to optimize antibiotic usage. Clin Microbiol Infect 24(1):3–5CrossRefPubMed Ruppé E, Burdet C, Grall N, de Lastours V, Lescure FX, Andremont A, Armand-Lefèvre L (2018) Impact of antibiotics on the intestinal microbiota needs to be re-defined to optimize antibiotic usage. Clin Microbiol Infect 24(1):3–5CrossRefPubMed
4.
go back to reference Nobel YR, Cox LM, Kirigin FF, Bokulich NA, Yamanishi S, Teitler I, Chung J, Sohn J, Barber CM, Goldfarb DS, Raju K, Abubucker S, Zhou Y, Ruiz VE, Li H, Mitreva M, Alekseyenko AV, Weinstock GM, Sodergren E, Blaser MJ (2015) Metabolic and metagenomic outcomes from early-life pulsed antibiotic treatment. Nat Commun 6:7486CrossRefPubMedPubMedCentral Nobel YR, Cox LM, Kirigin FF, Bokulich NA, Yamanishi S, Teitler I, Chung J, Sohn J, Barber CM, Goldfarb DS, Raju K, Abubucker S, Zhou Y, Ruiz VE, Li H, Mitreva M, Alekseyenko AV, Weinstock GM, Sodergren E, Blaser MJ (2015) Metabolic and metagenomic outcomes from early-life pulsed antibiotic treatment. Nat Commun 6:7486CrossRefPubMedPubMedCentral
5.
go back to reference Pérez-Cobas AE, Artacho A, Knecht H, Ferrús ML, Friedrichs A, Ott SJ, Moya A, Latorre A, Gosalbes MJ (2013) Differential effects of antibiotic therapy on the structure and function of human gut microbiota. PLoS One 8(11):e80201CrossRefPubMedPubMedCentral Pérez-Cobas AE, Artacho A, Knecht H, Ferrús ML, Friedrichs A, Ott SJ, Moya A, Latorre A, Gosalbes MJ (2013) Differential effects of antibiotic therapy on the structure and function of human gut microbiota. PLoS One 8(11):e80201CrossRefPubMedPubMedCentral
6.
go back to reference Laukens D, Brinkman BM, Raes J, De Vos M, Vandenabeele P (2016) Heterogeneity of the gut microbiome in mice: guidelines for optimizing experimental design. FEMS Microbiol Rev 40(1):117–132CrossRefPubMed Laukens D, Brinkman BM, Raes J, De Vos M, Vandenabeele P (2016) Heterogeneity of the gut microbiome in mice: guidelines for optimizing experimental design. FEMS Microbiol Rev 40(1):117–132CrossRefPubMed
7.
go back to reference Raes J (2016 Jun) Microbiome-based companion diagnostics: no longer science fiction? Gut 65(6):896–897CrossRefPubMed Raes J (2016 Jun) Microbiome-based companion diagnostics: no longer science fiction? Gut 65(6):896–897CrossRefPubMed
8.
go back to reference Haldar K, Bafadhel M, Lau K, Berg A, Kwambana B, Kebadze T, Ramsheh MY, Barker B, Haldar P, Johnston S, Ketley JM, Brightling CE, Barer MR (2017) Microbiome balance in sputum determined by PCR stratifies COPD exacerbations and shows potential for selective use of antibiotics. PLoS One 12(8):e0182833CrossRefPubMedPubMedCentral Haldar K, Bafadhel M, Lau K, Berg A, Kwambana B, Kebadze T, Ramsheh MY, Barker B, Haldar P, Johnston S, Ketley JM, Brightling CE, Barer MR (2017) Microbiome balance in sputum determined by PCR stratifies COPD exacerbations and shows potential for selective use of antibiotics. PLoS One 12(8):e0182833CrossRefPubMedPubMedCentral
9.
go back to reference Langdon A, Crook N, Dantas G (2016) The effects of antibiotics on the microbiome throughout development and alternative approaches for therapeutic modulation. Genome Med 8(1):39CrossRefPubMedPubMedCentral Langdon A, Crook N, Dantas G (2016) The effects of antibiotics on the microbiome throughout development and alternative approaches for therapeutic modulation. Genome Med 8(1):39CrossRefPubMedPubMedCentral
10.
go back to reference Brown KA, Khanafer N, Daneman N, Fisman DN (2013) Meta-analysis of antibiotics and the risk of community-associated Clostridium difficile infection. Antimicrob Agents Chemother 57(5):2326–2332CrossRefPubMedPubMedCentral Brown KA, Khanafer N, Daneman N, Fisman DN (2013) Meta-analysis of antibiotics and the risk of community-associated Clostridium difficile infection. Antimicrob Agents Chemother 57(5):2326–2332CrossRefPubMedPubMedCentral
12.
go back to reference Saari A, Virta LJ, Sankilampi U, Dunkel L, Saxen H (2015) Antibiotic exposure in infancy and risk of being overweight in the first 24 months of life. Pediatrics 135(4):617–626CrossRefPubMed Saari A, Virta LJ, Sankilampi U, Dunkel L, Saxen H (2015) Antibiotic exposure in infancy and risk of being overweight in the first 24 months of life. Pediatrics 135(4):617–626CrossRefPubMed
13.
go back to reference Van Herk W, el Helou S, Janota J, Hagmann C, Klingenberg C, Staub E, Giannoni E, Tissieres P, Schlapbach LJ, van Rossum AM, Pilgrim SB, Stocker M (2016) Variation in current management of term and late-preterm neonates at risk for early-onset sepsis: an international survey and review of guidelines. Pediatr Infect Dis J 35(5):494–500CrossRefPubMed Van Herk W, el Helou S, Janota J, Hagmann C, Klingenberg C, Staub E, Giannoni E, Tissieres P, Schlapbach LJ, van Rossum AM, Pilgrim SB, Stocker M (2016) Variation in current management of term and late-preterm neonates at risk for early-onset sepsis: an international survey and review of guidelines. Pediatr Infect Dis J 35(5):494–500CrossRefPubMed
15.
go back to reference Beaudoin T, Yau YCW, Stapleton PJ, Gong Y, Wang PW, Guttman DS, Waters V (2017) Staphylococcus aureus interaction with Pseudomonas aeruginosa biofilm enhances tobramycin resistance. NPJ Biofilms Microbiomes 3:25CrossRefPubMedPubMedCentral Beaudoin T, Yau YCW, Stapleton PJ, Gong Y, Wang PW, Guttman DS, Waters V (2017) Staphylococcus aureus interaction with Pseudomonas aeruginosa biofilm enhances tobramycin resistance. NPJ Biofilms Microbiomes 3:25CrossRefPubMedPubMedCentral
16.
go back to reference Sherrard LJ, McGrath SJ, McIlreavey L, Hatch J, Wolfgang MC, Muhlebach MS, Gilpin DF, Elborn JS, Tunney MM (2016) Production of extended-spectrum β-lactamases and the potential indirect pathogenic role of Prevotella isolates from the cystic fibrosis respiratory microbiota. Int J Antimicrob Agents 47(2):140–145CrossRefPubMed Sherrard LJ, McGrath SJ, McIlreavey L, Hatch J, Wolfgang MC, Muhlebach MS, Gilpin DF, Elborn JS, Tunney MM (2016) Production of extended-spectrum β-lactamases and the potential indirect pathogenic role of Prevotella isolates from the cystic fibrosis respiratory microbiota. Int J Antimicrob Agents 47(2):140–145CrossRefPubMed
17.
go back to reference Pustelny C, Komor U, Pawar V, Lorenz A, Bielecka A, Moter A, Gocht B, Eckweiler D, Müsken M, Grothe C, Lünsdorf H, Weiss S, Häussler S (2015) Contribution of Veillonella parvula to Pseudomonas aeruginosa-mediated pathogenicity in a murine tumor model system. Infect Immun 83(1):417–429CrossRefPubMed Pustelny C, Komor U, Pawar V, Lorenz A, Bielecka A, Moter A, Gocht B, Eckweiler D, Müsken M, Grothe C, Lünsdorf H, Weiss S, Häussler S (2015) Contribution of Veillonella parvula to Pseudomonas aeruginosa-mediated pathogenicity in a murine tumor model system. Infect Immun 83(1):417–429CrossRefPubMed
18.
go back to reference Sommer MO, Dantas G (2011 Oct) Antibiotics and the resistant microbiome. Curr Opin Microbiol 14(5):556–563CrossRefPubMed Sommer MO, Dantas G (2011 Oct) Antibiotics and the resistant microbiome. Curr Opin Microbiol 14(5):556–563CrossRefPubMed
19.
go back to reference Lagier JC, Khelaifia S, Alou MT, Ndongo S, Dione N, Hugon P, Caputo A, Cadoret F, Traore SI, Seck EH, Dubourg G, Durand G, Mourembou G, Guilhot E, Togo A, Bellali S, Bachar D, Cassir N, Bittar F, Delerce J, Mailhe M, Ricaboni D, Bilen M, Dangui Nieko NP, Dia Badiane NM, Valles C, Mouelhi D, Diop K, Million M, Musso D, Abrahão J, Azhar EI, Bibi F, Yasir M, Diallo A, Sokhna C, Djossou F, Vitton V, Robert C, Rolain JM, La Scola B, Fournier PE, Levasseur A, Raoult D (2016) Culture of previously uncultured members of the human gut microbiota by culturomics. Nat Microbiol 1:16203CrossRefPubMed Lagier JC, Khelaifia S, Alou MT, Ndongo S, Dione N, Hugon P, Caputo A, Cadoret F, Traore SI, Seck EH, Dubourg G, Durand G, Mourembou G, Guilhot E, Togo A, Bellali S, Bachar D, Cassir N, Bittar F, Delerce J, Mailhe M, Ricaboni D, Bilen M, Dangui Nieko NP, Dia Badiane NM, Valles C, Mouelhi D, Diop K, Million M, Musso D, Abrahão J, Azhar EI, Bibi F, Yasir M, Diallo A, Sokhna C, Djossou F, Vitton V, Robert C, Rolain JM, La Scola B, Fournier PE, Levasseur A, Raoult D (2016) Culture of previously uncultured members of the human gut microbiota by culturomics. Nat Microbiol 1:16203CrossRefPubMed
21.
go back to reference Joensen KG, Engsbro ALØ, Lukjancenko O, Kaas RS, Lund O, Westh H, Aarestrup FM (2017) Evaluating next-generation sequencing for direct clinical diagnostics in diarrhoeal disease. Eur J Clin Microbiol Infect Dis 36(7):1325–1338CrossRefPubMedPubMedCentral Joensen KG, Engsbro ALØ, Lukjancenko O, Kaas RS, Lund O, Westh H, Aarestrup FM (2017) Evaluating next-generation sequencing for direct clinical diagnostics in diarrhoeal disease. Eur J Clin Microbiol Infect Dis 36(7):1325–1338CrossRefPubMedPubMedCentral
22.
go back to reference Dunham SJ, Ellis JF, Li B, Sweedler JV (2017 Jan 17) Mass spectrometry imaging of complex microbial communities. Acc Chem Res 50(1):96–104CrossRefPubMed Dunham SJ, Ellis JF, Li B, Sweedler JV (2017 Jan 17) Mass spectrometry imaging of complex microbial communities. Acc Chem Res 50(1):96–104CrossRefPubMed
23.
go back to reference Liu S, Chen P, Zhang N, Sun L, Dai G, Zhu L, Li C, Zhao Y, Zhang L, Fu H, Ju W (2017) Comprehensive characterization of the in vitro and in vivo metabolites of limonin in human samples using LC-Q-TOF/MS. J Chromatogr B Analyt Technol Biomed Life Sci 1068-1069:226–232CrossRefPubMed Liu S, Chen P, Zhang N, Sun L, Dai G, Zhu L, Li C, Zhao Y, Zhang L, Fu H, Ju W (2017) Comprehensive characterization of the in vitro and in vivo metabolites of limonin in human samples using LC-Q-TOF/MS. J Chromatogr B Analyt Technol Biomed Life Sci 1068-1069:226–232CrossRefPubMed
24.
go back to reference Van Nood E, Vrieze A, Nieuwdorp M, Fuentes S, Zoetendal EG, de Vos WM, Visser CE, Kuijper EJ, Bartelsman JF, Tijssen JG, Speelman P, Dijkgraaf MG, Keller JJ (2013) Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 368(5):407–415CrossRefPubMed Van Nood E, Vrieze A, Nieuwdorp M, Fuentes S, Zoetendal EG, de Vos WM, Visser CE, Kuijper EJ, Bartelsman JF, Tijssen JG, Speelman P, Dijkgraaf MG, Keller JJ (2013) Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 368(5):407–415CrossRefPubMed
25.
go back to reference Buffie CG, Bucci V, Stein RR, McKenney PT, Ling L, Gobourne A, No D, Liu H, Kinnebrew M, Viale A, Littmann E, van den Brink MR, Jenq RR, Taur Y, Sander C, Cross JR, Toussaint NC, Xavier JB, Pamer EG (2015) Precision microbiome reconstitution restores bile acid mediated resistance to Clostridium difficile. Nature 517(7533):205–208CrossRefPubMed Buffie CG, Bucci V, Stein RR, McKenney PT, Ling L, Gobourne A, No D, Liu H, Kinnebrew M, Viale A, Littmann E, van den Brink MR, Jenq RR, Taur Y, Sander C, Cross JR, Toussaint NC, Xavier JB, Pamer EG (2015) Precision microbiome reconstitution restores bile acid mediated resistance to Clostridium difficile. Nature 517(7533):205–208CrossRefPubMed
26.
go back to reference Hoffmann D, Palumbo F, Ravel J, Roghmann MC, Rowthorn V, von Rosenvinge E (2017) Improving regulation of microbiota transplants. Science 358(6369):1390–1391CrossRefPubMedPubMedCentral Hoffmann D, Palumbo F, Ravel J, Roghmann MC, Rowthorn V, von Rosenvinge E (2017) Improving regulation of microbiota transplants. Science 358(6369):1390–1391CrossRefPubMedPubMedCentral
Metadata
Title
Antibiotic treatment and stewardship in the era of microbiota-oriented diagnostics
Authors
Debby Bogaert
Alex van Belkum
Publication date
01-05-2018
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Clinical Microbiology & Infectious Diseases / Issue 5/2018
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-018-3198-6

Other articles of this Issue 5/2018

European Journal of Clinical Microbiology & Infectious Diseases 5/2018 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.